ProfileGDS5678 / 1436232_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 70% 77% 70% 74% 69% 70% 70% 70% 69% 73% 75% 72% 72% 71% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.3463770
GSM967853U87-EV human glioblastoma xenograft - Control 25.2036877
GSM967854U87-EV human glioblastoma xenograft - Control 34.4103870
GSM967855U87-EV human glioblastoma xenograft - Control 44.9731374
GSM967856U87-EV human glioblastoma xenograft - Control 54.2448369
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.3690270
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.3389270
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.3889870
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.2673369
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.6833573
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.9549775
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.6286272
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.5249572
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.4070971